Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Relay Therapeutics Inc ( (RLAY)) has released its Q3 earnings. Here is a breakdown of the information Relay Therapeutics Inc presented to its investors. Relay Therapeutics Inc., a clinical-stage ...

Coya Therapeutics, Inc. ( (COYA)) has released its Q3 earnings. Here is a breakdown of the information Coya Therapeutics, Inc. presented to its investors. Coya Therapeutics, Inc. is a clinical ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CytoMed Therapeutics Limited has expanded its biopharmaceutical focus on cell-based therapies by acquiring a Malaysian cord blood banking license and corresponding assets, including ...

SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 /Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB ("Alligator") (ATORX) today announced that new, positive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

Dyne Therapeutics Inc.-2.70% $2.94B ...